Clinical trials: HIP AND KNEE OSTEOARTHRITIS
- Condition HIP AND KNEE OSTEOARTHRITIS
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Osteoarthritis
Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment
The main purpose of this study is to evaluate how a long-term treatment with Theraflex during 64 weeks affects pain intensity in the affected knee or hip joint, the activity in daily living, the quality of life and patient…
- Trial name
- NCT03330288
- Testing
- Theraflex, BAY 874017
- Where
- 2 sites in Russia
- Volunteers
- 1,102 people
- Sponsor
- Bayer
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
The objective of this exploratory study is to evaluate the cellular and connective tissue composition of joints from patients with Osteoarthritis (OA) who have been treated with fasinumab, compared with those treated with placebo…
- Trial name
- NCT03949673
- Testing
- Fasinumab, Naproxen, Diclofenac
- Where
- 15 sites in United States, Poland and 1 more
- Volunteers
- 23 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the effect of fasinumab compared to placebo on peripheral nerves in participants with pain due to Osteoarthritis (OA) of the hip or knee.
- Trial name
- NCT03691974
- Testing
- Fasinumab
- Where
- 47 sites in United States, Poland and 1 more
- Volunteers
- 180 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis
Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly
The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).
- Trial name
- NCT00324038
- Testing
- Buprenorphine, Codeine paracetamol
- Where
- United Kingdom
- Volunteers
- 219 people
- Sponsor
- Napp Pharmaceuticals Limited
Osteoarthritis, Hip, Osteoarthritis, Knee
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back…
- Conditions
- Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
- Trial name
- NCT00361504
- Testing
- Oxycodone CR, Tapentadol (CG5503) ER
- Where
- 52 sites in United States, Canada
- Volunteers
- 1,123 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Osteoarthritis
Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip
The purpose of this study is to evaluate the safety of Meloxicam SoluMatrix Capsules for up to 52 weeks in subjects with pain due to osteoarthritis (OA) of the knee or hip
- Trial name
- NCT01801735
- Testing
- Meloxicam Test Capsules
- Where
- 40 sites in United States
- Volunteers
- 600 people
- Sponsor
- Iroko Pharmaceuticals, LLC
Osteoarthritis, Knee, Osteoarthritis, Hip
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.
- Trial name
- NCT00139776
- Testing
- Celecoxib
- Where
- 124 sites in United States, Belgium and 6 more
- Volunteers
- 875 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Osteoarthritis, Knee / Osteoarthritis, Hip
Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain
The objective of this study is to verify the superiority of 16 weeks of MT-5547 treatment to placebo, as evidenced by the WOMAC pain score (the efficacy outcome measure), in patients with osteoarthritis of the knee or hip.
- Trial name
- NCT03245008
- Testing
- MT-5547
- Where
- 27 sites in Japan
- Volunteers
- 626 people
- Sponsor
- Tanabe Pharma Corporation
Osteoarthritis, Knee, Osteoarthritis, Hip
A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
The primary objective of the study is to evaluate the efficacy of fasinumab compared with placebo, when administered for up to 16 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.
- Trial name
- FACT OA1 (NCT03161093)
- Testing
- Fasinumab, Naproxen
- Where
- 139 sites in United States, Denmark and 10 more
- Volunteers
- 3,307 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Pain
A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain
To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain
- Trial name
- NCT00631319
- Testing
- OROS hydromorphone
- Volunteers
- 343 people
- Sponsor
- Mallinckrodt
Localized Primary Osteoarthritis of Hip, Localized Primary Osteoarthritis of Knee
Phase III Study of CG100649 in Osteoarthritis Patients
6-week Efficacy Study The objective of this study is to prove the safety and non-inferiority of analgesic efficacy of CG100649 2 mg vs. celecoxib 200 mg, and analgesic superiority of CG100649 2 mg vs.
- Trial name
- NCT01765296
- Testing
- CG100649, Celecoxib
- Where
- 14 sites in South Korea
- Volunteers
- 362 people
- Sponsor
- CrystalGenomics, Inc.
Osteoarthritis, Knee, Osteoarthritis, Hip
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at Week 8, compared to giving 2 doses of…
- Trial name
- NCT02697773
- Testing
- Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
- Where
- 87 sites in United States, Canada and 1 more
- Volunteers
- 698 people
- Sponsor
- Pfizer
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.
- Trial name
- FACT OA2 (NCT03304379)
- Testing
- Fasinumab, Diclofenac, Celecoxib
- Where
- 71 sites in United States
- Volunteers
- 1,650 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
A4091064 is a multicenter, long-term observational study of subjects from tanezumab interventional studies (regardless of treatment group) who undergo a total knee, hip or shoulder replacement during participation in the study.
- Trial name
- NCT02674386
- Testing
- Investigational Medical Product (IMP) administered in parent study
- Where
- 79 sites in United States, Australia and 13 more
- Volunteers
- 154 people
- Sponsor
- Pfizer
Osteoarthritis
Tanezumab in Osteoarthritis of the Hip or Knee (2)
Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis
- Trial name
- NCT00863304
- Testing
- tanezumab 10 mg, tanezumab 5 mg, naproxen
- Where
- 95 sites in United States
- Volunteers
- 849 people
- Sponsor
- Pfizer
Osteoarthritis
Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients
Tanezumab, administered for up to 1 1/2 years, reduces the pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves
- Trial name
- NCT00960804
- Testing
- Tanezumab
- Where
- 18 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Pain, Osteoarthritis, Hip
Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee
This clinical trial tests the pain relieving effectiveness of OROS hydromorphone, a once-daily formulation of a strong opioid against placebo in patients, who are suffering from pain due to osteoarthritis of the hip or the knee…
- Conditions
- Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
- Trial name
- NCT00980798
- Testing
- OROS hydromorphone HCl
- Where
- 12 sites in Czechia, Romania and 2 more
- Volunteers
- 288 people
- Sponsor
- Janssen-Cilag International NV
Osteoarthritis of the Knee or Hip
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
- Trial name
- FACT LTS & OA (NCT02683239)
- Testing
- Fasinumab
- Where
- 149 sites in United States, Bulgaria and 19 more
- Volunteers
- 5,331 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis
Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
- Trial name
- NCT01141283
- Testing
- Buprenorphine transdermal patch
- Where
- 42 sites in United States
- Volunteers
- 290 people
- Sponsor
- Purdue Pharma LP
Osteoarthritis
Extension Study Of Tanezumab In Osteoarthritis
Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
- Trial name
- NCT00809783
- Testing
- tanezumab
- Where
- 226 sites in United States
- Volunteers
- 2,147 people
- Sponsor
- Pfizer